Join the 'Kogenate FS with Bioset' group to help and get support from people like you.
Kogenate FS with Bioset News
Posted 31 Jul 2015 by Drugs.com
FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in California with serious chronic illnesses. The study "underscores the potential effect of new, expensive but [effective] pharmaceuticals on public insurance programs for children with chronic illness," wrote a group led by Sonja Swenson of Stanford University. Her team published the findings July 28 in the Journal of the American Medical Association. The researchers tracked 2010-2012 data from more than 34,300 publicly insured children and young adults under the age of 21 in California with serious ... Read more
Related support groups: Hemophilia A, Hemophilia B, Antihemophilic Factor, Hemophilia, ReFacto, Humate-P, Advate, Hyate:C, Xyntha, Monoclate, Eloctate, Genarc, Koate-HP, Advate rAHF-PFM, Optivate, Helixate, Kogenate Bayer, Hemophilia A with Inhibitors, Beriate P, Helixate NexGen